High-Performance Plasma Biomarker Panel for Alzheimer's Disease Screening Using a Femtomolar-Level Label-Free Biosensing System.
High-Performance Plasma Biomarker Panel for Alzheimer's Disease Screening Using a Femtomolar-Level Label-Free Biosensing System.
复制标题
高性能血浆生物标志物面板阿尔茨海默病筛查使用飞秒级无标记生物传感系统。
DOI：
10.1021/acsnano.3c09311
复制
发表时间：
2023-12
期刊：
影响因子：
17.1
通讯作者：
Shicai Wang;Ruijun Deng;Zhiya Chen;Lili Huang;Yang Song;Dan Yuan;Yu Li;Haonan Liu;Fan Yang;Beiyuan Fan;Yun Xu;Zijian Zhao;Yanzhao Li;Yan Zhang
中科院分区：
文献类型：
--
作者：
Shicai Wang;Ruijun Deng;Zhiya Chen;Lili Huang;Yang Song;Dan Yuan;Yu Li;Haonan Liu;Fan Yang;Beiyuan Fan;Yun Xu;Zijian Zhao;Yanzhao Li;Yan Zhang
阿尔茨海默病（AD）是老年人痴呆症的最常见原因。然而，通过非认知方法诊断AD，如侵入性脑脊液采样或放射性正电子发射断层扫描，应用有限。在此，使用超灵敏石墨烯场效应晶体管传感器在多中心临床队列中测定人血浆中AD生物标志物淀粉样蛋白β 40（Aβ40）、淀粉样蛋白β 42（Aβ42）、磷酸化tau 181（P-tau 181）、磷酸化tau 217（P-tau 217）和神经丝轻链（NfL）的飞摩尔水平。还使用机器学习算法来组装这些血浆生物标志物，并优化它们在区分阿尔茨海默氏痴呆症进展的各个阶段中的性能。“composite-info”生物标志物面板结合了这些生物标志物和临床信息，大大改善了AD进展的分期性能。在受试者操作特征（ROC）曲线中，其曲线下面积>0.94。此外，与简易精神状态检查/蒙特利尔认知评估和核磁共振成像相比，该小组在基于个人的阶段评估中表现出优势。这项研究提供了一个复合生物标志物面板的筛选和早期诊断AD使用快速检测系统。
Alzheimer's disease (AD) is the most common cause of dementia in older people. However, diagnosing AD through noncognitive methods, such as invasive cerebrospinal fluid sampling or radioactive positron emission tomography, has limited applications. Herein, the femtomolar levels of AD biomarkers amyloid β 40 (Aβ40), amyloid β 42 (Aβ42), phosphorylated tau 181 (P-tau181), phosphorylated tau 217 (P-tau217), and neurofilament light chain (NfL) were determined in human plasma in multicenter clinical cohorts using an ultrasensitive graphene field-effect transistor sensor. A machine-learning algorithm was also used to assemble these plasma biomarkers and optimize their performance in discriminating individual stages of Alzheimer's dementia progression. The "composite-info" biomarker panel, which combines these biomarkers and clinical information, considerably improved the staging performance in AD progression. It achieved an area under the curve of >0.94 in the receiver operator characteristic (ROC) curve. In addition, the panel demonstrated an advantage in the individual-based stage assessment compared with that of the Mini-Mental State Examination/Montreal Cognitive Assessment and nuclear magnetic resonance imaging. This study provides a composite biomarker panel for the screening and early diagnosis of AD using a rapid detection system.